Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Angle Strikes Out Into New Cancer Dx Markets

This article was originally published in Clinica

Executive Summary

Angle is moving ahead with plans to take its Parsortix circulating tumor cell capture technology into the prostate and breast cancer diagnostic markets after securing £10.2m ($15m) in new capital through a share placement.

Advertisement

Related Content

Liquid Biopsy In Oncology: An Increasingly Crowded Landscape
Small-Cap Recap: Fiscal 2016 Spells Sea Change For Angle; Cellnovo; Novacyt; Nanobiotix

Topics

Advertisement
UsernamePublicRestriction

Register

MT103454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel